Viewing StudyNCT04647110



Ignite Creation Date: 2024-05-06 @ 3:27 PM
Last Modification Date: 2024-10-26 @ 1:50 PM
Study NCT ID: NCT04647110
Status: COMPLETED
Last Update Posted: 2023-04-06
First Post: 2020-11-25

Brief Title: Real-world Therapy of ALK-positive NSCLC in Sweden the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers
Sponsor: Pfizer
Organization: Pfizer

Key Dates - Follows AllAPIJSON File Order

Start Date: 2020-12-14
Start Date Type: ACTUAL
Primary Completion Date: 2021-03-15
Primary Completion Date Type: ACTUAL
Completion Date: 2021-03-15
Completion Date Type: ACTUAL
First Submit Date: 2020-11-25
First Submit QC Date: November 25 2020
Study First Post Date: 2020-11-30
Study First Post Date Type: ACTUAL
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: 2022-07-13
Results First Post Date Type: ACTUAL
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2023-04-04
Last Update Post Date: 2023-04-06
Last Update Post Date Type: ACTUAL